Search
  • Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2019 year
    09
    05 day
    Strategic Cooperation Agreement on Flumarin Achieved between Winhealth and Shionogi

    On September 5 2019, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as “Winhealth Group”) announced that it has entered into a strategic cooperation agreement with Shionogi & Co Ltd (hereinafter referred to as “Shionogi”) for the product Flumarin. Shionogi will grant Winhealth Group the Exclusive License of Flumarin in mainland China, fully authorizing Winhealth of its commercial operation in mainland China from registration, access, marketing, channel management to product life cycle management.


    Flumenine (cefosporin fluoride), produced by Shionogi & Co Ltd, is a broad-spectrum antibacterial agent of oxygen cefosporin (oxycephalosporin). It has anti-exomycin, streptococcus, propionibacterium, and methicillin-resistant and sensitive Staphylococcus aureus activity. Flomoxef has broad-spectrum antibacterial activity against gram-positive bacteria, gram-negative bacteria and even anaerobic bacteria such as Staphylococcus aureus, Escherichia coli and Bacteroides, and it can be used alone for effective treatment against both anaerobic infection and aerobic infection (mixed infection).


    Strategic Cooperation Agreement on Flumarin Achieved between Winhealth and Shionogi Strategic Cooperation Agreement on Flumarin Achieved between Winhealth and Shionogi


    The diagnosis and early appropriate treatment of ESBLs–producing enterobacteriacea infection has become an important clinical problem that needs to be solved urgently. The detection rate of escherichia coli and klebsiella pneumoniae ESBLs in mainland China is very high and trends to increase year by year [1]. CHINET Surveillance in 2010 showed that the detection rates of Escherichia coli and Klebsiella pneumoniae in blood culture bacteria are 15% and 6.0%, ranking the first and second place in gram-negative bacteria [2], among which the proportion of ESBLs-producing are 50.7% and 38.5%[3] respectively. Cephalospora fluoroxide is very stable against β-lactamase and extended-spectrum β-lactamase (ESBL). Flumenine has good activity against ESBL-producing enterobacteriaceae and is an option for treating infections caused by ESBL-producing enterobacteriaceae.


    Since this is the first cooperation between Winhealth Group and Shionogi, Winhealth Group is going to devote its diversified national marketing network, and academic-based customized marketing strategy to continuously covering the product life cycle, helping the clinical treatment of Chinese patients, and further promoting the development of China's health industry.


    Strategic Cooperation Agreement on Flumarin Achieved between Winhealth and Shionogi


    “We are looking forward to this cooperation. As like-minded partners, both Shionogi and Winhealth Group hope to help more patients with the best medicine and bring good news to Chinese patients.” Said John Keller, Senior Executive Officer Senior Vice President Global Business Division from Shionogi & Co Ltd.


    Mr. Wang Wei, President of Winhealth Group, pointed out that 'As a classic original anti-bacterial drug, flumanin (cefosporin fluoride) is highly in line with the company's 2.0 product portfolio strategy. It’s our great pleasure cooperate with such excellent pharmaceutical enterprise as Shionogi. It has been Winhealth’s mission to focus on the Chinese market, to bring faster and more efficient access and commercialization of the world's high-quality new special medicine products, and to benefit hundreds of millions of patients. We will also make every effort to bring Flumarin to patients in need, and providing them with treatment so that they can go back to health and enjoy life as soon as possible.


    About Hongkong Winhealth Pharma Group Co., Ltd.

    Founded in Hangzhou 2006, Winhealth Group is headquartered in Hong Kong, China. It is a one-stop professional service platform focusing on drug registration, product import, market access, commercialization and life cycle management.

    As a new pharmaceutical company that promotes the development of China's pharmaceutical health industry. Winhealth Group is committed to bringing the world's leading health products and medical technology to the Chinese market, providing medical professionals with more excellent treatments and medical information dissemination channels, and at the same time providing patients with more treatment and rehabilitation resources. It is built as a leading full-cycle, integrated and customized market access solution provider and commercial development service platform (CDCO, Contract Development and Commercialization Organization).

    For more information, please visit the official website of Hongkong Winhealth Pharma Group Co., Ltd.: http://www.winhealth.hk/.



    About Shionogi & Co Ltd.

    Shionogi & Co., Ltd. is a major Japanese research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of 'supplying the best possible medicine to protect the health and wellbeing of the patients we serve.' The company currently markets products in several therapeutic areas including anti-infectives, pain, cardiovascular diseases and gastroenterology. Our pipeline is focused on infectious disease, pain and CNS. For more information on Shionogi & Co., Ltd., please visit www.shionogi.co.jp/en.


    References:

    [1] Expert Consensus Statement on Countermeasures of Chinese Extended-spectrum β-lactamase against Enterobacteriaceae Bacterial Infection [J]. Chinese Medical Journal, 2014, 94(24): 1847-1856, Zhou Hua, Li Guanghui, Chen Yuyi et al.

    [2] CHINET 2010 Surveillance of Bacterial Resistance in China [J]. Chinese Journal of Infection and Chemotherapy 2011 11:321-329, Zhu Demei, Wang Fu, Hu Fupin et al.

    [3] CHINET 2011 Surveillance of Bacterial Resistance in China [J]. Chinese Journal of Infection and Chemotherapy 2012, 12:321-329, Hu Fupin, Zhu Demei, Wang Fu et al.

    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358    4008393773 ( Product Hotline )
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.